Mary M. Rozenman Sells 25,000 Shares of Aimmune Therapeutics Inc. (AIMT) Stock
Aimmune Therapeutics Inc. (NASDAQ:AIMT) insider Mary M. Rozenman sold 25,000 shares of the business’s stock in a transaction dated Wednesday, October 5th. The stock was sold at an average price of $16.80, for a total value of $420,000.00. Following the sale, the insider now owns 25,000 shares of the company’s stock, valued at approximately $420,000. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Aimmune Therapeutics Inc. (NASDAQ:AIMT) opened at 16.55 on Friday. The firm has a 50-day moving average price of $15.53 and a 200-day moving average price of $13.65. The stock’s market cap is $699.30 million. Aimmune Therapeutics Inc. has a 12-month low of $9.77 and a 12-month high of $22.01.
Aimmune Therapeutics (NASDAQ:AIMT) last released its quarterly earnings results on Wednesday, August 10th. The company reported ($0.43) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.42) by $0.01. Analysts forecast that Aimmune Therapeutics Inc. will post ($1.75) EPS for the current fiscal year.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/08/mary-m-rozenman-sells-25000-shares-of-aimmune-therapeutics-inc-aimt-stock.html
A number of analysts have recently issued reports on AIMT shares. Zacks Investment Research upgraded Aimmune Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, September 19th. Wedbush reiterated a “buy” rating and set a $42.00 target price on shares of Aimmune Therapeutics in a report on Wednesday, August 24th. Piper Jaffray Cos. reiterated an “overweight” rating and set a $38.00 target price on shares of Aimmune Therapeutics in a report on Friday, September 23rd. Finally, Credit Suisse Group AG reiterated a “buy” rating and set a $35.00 target price on shares of Aimmune Therapeutics in a report on Friday, August 19th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $32.20.
A number of large investors have recently made changes to their positions in the company. Metropolitan Life Insurance Co. NY increased its stake in shares of Aimmune Therapeutics by 9.0% in the first quarter. Metropolitan Life Insurance Co. NY now owns 9,617 shares of the company’s stock valued at $130,000 after buying an additional 797 shares in the last quarter. Emerald Acquisition Ltd. acquired a new stake in shares of Aimmune Therapeutics during the second quarter valued at about $154,000. American International Group Inc. increased its stake in shares of Aimmune Therapeutics by 135.7% in the second quarter. American International Group Inc. now owns 15,131 shares of the company’s stock valued at $164,000 after buying an additional 8,711 shares in the last quarter. Nationwide Fund Advisors increased its stake in shares of Aimmune Therapeutics by 127.7% in the second quarter. Nationwide Fund Advisors now owns 16,929 shares of the company’s stock valued at $183,000 after buying an additional 9,495 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new stake in shares of Aimmune Therapeutics during the second quarter valued at about $186,000. 68.87% of the stock is owned by hedge funds and other institutional investors.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics Inc, formerly Allergen Research Corporation, is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach, including the development of proprietary candidates, for the treatment of peanut and other food allergies. The Company’s Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.